Sonoma Pharmaceuticals, Inc. Uncategorized Contracts & Agreements
102 Contracts & Agreements
- Offer letter to John Dal Poggetto dated February 7, 2024 (Filed With SEC on February 8, 2024)
- Offer letter to Jerome Dvonch dated February 7, 2024 (Filed With SEC on February 8, 2024)
- Offer letter to John Dal Poggetto dated July 11, 2023 (Filed With SEC on July 14, 2023)
- Amendment to At-The-Market Offering Agreement, by and between the Company and Ladenburg Thalmann & Co. Inc., dated February 24, 2023 (Filed With SEC on February 24, 2023)
- At-The-Market Offering Agreement, by and between the Company and Ladenburg Thalmann & Co. Inc., dated December 23, 2022 (Filed With SEC on December 23, 2022)
- Offer letter to Chad White dated September 8, 2022 (Filed With SEC on October 7, 2022)
- At-The-Market Offering Agreement, by and between the Company and H.C. Wainwright & Co., LLC, dated July 30, 2021 (Filed With SEC on July 30, 2021)
- Offer letter J. Dvonch dated August 10, 2020 (Filed With SEC on September 11, 2020)
- Licensing Agreement between Sonoma Pharmaceuticals, Inc. and Microsafe Group, effective July 27, 2020 (Filed With SEC on August 6, 2020)
- Master Vendor Agreement by and between Sonoma Pharmaceuticals, Inc. and PetSmart Home Office, Inc., dated November 21, 2016 (Filed With SEC on June 28, 2017)
- BACKGROUND (Filed With SEC on October 31, 2016)
- BACKGROUND (Filed With SEC on October 31, 2016)
- SECURITIESPURCHASE AGREEMENT (Filed With SEC on February 26, 2014)
- Oculus Innovative Sciences, Inc. 1129 North McDowell Boulevard Petaluma, CA 94954 (Filed With SEC on November 19, 2013)
- ADDENDUM TO STANDARD INDUSTRIAL/COMMERCIALMULTI-TENANT LEASE-GROSS BY AND BETWEEN KCMKCPROPERTIES, LLP, AS LESSOR, AND OCULUS INC. A DELAWARE CORPORATION, AS LESSEE FOR THE... (Filed With SEC on November 8, 2012)
- Venture Lending & Leasing VI, Inc. 104 La Mesa Dr., Suite 102 Portola Valley, CA 94028 October 30, 2012 (Filed With SEC on November 1, 2012)
- Venture Lending & Leasing V, Inc. 104 La Mesa Dr., Suite 102 Portola Valley, CA 94028 October 30, 2012 (Filed With SEC on November 1, 2012)
- STOCKPURCHASE AGREEMENT (Filed With SEC on November 1, 2012)
- SUPPLEMENT (Filed With SEC on July 6, 2011)
- PRODUCTOPTION AGREEMENT (Filed With SEC on February 18, 2011)
- EXCLUSIVECO-PROMOTION AGREEMENT (Filed With SEC on February 18, 2011)
- DISTRIBUTIONAGREEMENT (Filed With SEC on February 4, 2011)
- PURCHASEAGREEMENT (Filed With SEC on November 4, 2010)
- SECURITIESPURCHASE AGREEMENT (Filed With SEC on November 4, 2010)
- Exhibit10.1 CONTINUOUSOFFERING PROGRAM AGREEMENT (Filed With SEC on September 17, 2010)
- We may move forward into the pivotal phase of our U.S. clinical program for Microcyn Technology (Filed With SEC on June 11, 2009)
- We may move forward into the pivotal phase of our U.S. clinical program for Microcyn Technology (Filed With SEC on June 11, 2009)
- We may move forward into the pivotal phase of our U.S. clinical program for Microcyn Technology (Filed With SEC on June 11, 2009)
- We may move forward into the pivotal phase of our U.S. clinical program for Microcyn Technology (Filed With SEC on June 11, 2009)
- Entry Into a Material Definitive Agreement (Filed With SEC on February 27, 2009)
- Entry Into a Material Definitive Agreement (Filed With SEC on February 27, 2009)
- Current assets (Filed With SEC on August 6, 2008)
- Complete a meeting with FDA regarding our Phase II results and pivotal trial protocols (Filed With SEC on June 13, 2008)
- Complete a meeting with FDA regarding our Phase II results and pivotal trial protocols (Filed With SEC on June 13, 2008)
- ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT (Filed With SEC on March 28, 2008)
- ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT (Filed With SEC on March 28, 2008)
- ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT (Filed With SEC on March 28, 2008)
- Initiate and complete Phase II trial for use of Microcyn in the treatment of infections in mildly infected diabetic foot ulcers (Filed With SEC on June 20, 2007)
- Initiate and complete Phase II trial for use of Microcyn in the treatment of infections in mildly infected diabetic foot ulcers (Filed With SEC on June 20, 2007)
- Initiate and complete Phase II trial for use of Microcyn in the treatment of infections in mildly infected diabetic foot ulcers (Filed With SEC on June 20, 2007)
